Article Sidebar

pdf
Date Published: 25/08/2023
Abstract Views: 259
Views pdf: 210
DOI: https://doi.org/10.51298/vmj.v529i1.6232
Issue
Vol. 529 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn, Đình L., Đỗ, A. T., & Nguyễn, X. H. (2023). CLINICAL AND SUBCLINICAL CHARACTERISTICS OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). Vietnam Medical Journal, 529(1). https://doi.org/10.51298/vmj.v529i1.6232

CLINICAL AND SUBCLINICAL CHARACTERISTICS OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Đình Lợi Nguyễn1,, Anh Tú Đỗ2, Xuân Hậu Nguyễn1
1 HMU
2 K hospital

Main Article Content

Abstract

Objectives: Describe some clinical and subclinical characteristics of patients with castrastion-resistant metastatic prostate cancer. Patients and methods: A cross-sectional descriptive study on 65 patients with metastatic castration-resistant prostate cancer in Vietnam National Cancer Hospital from January 2014 through March 2023. Results: Mean age 70.12 ± 8.18 years, rate of patients receiving radical treatment at the time of initial diagnosis was 24.6%, median time from ADT to mCRPC was 16.0 months. Common symptoms were bone pain (55.4%), fatigue (43%), urinary retention/difficulty in urination (35.4%), urinary incontinence (29.2%). Bone was the most common site of metastasis (87.7%), median PSA was 34,7 ng/mL, mean hemoglobin is 122,4 g/L. Conclusion: Patients with castration-resistant metastatic prostate cancer have heterogeneous clinical and subclincal characteristics. The median time from ADT to CRPC was 16,0 months.

Article Details

Keywords

prostate cancer, castrastion resistance, clinical characteristics, subaclinical characteristics.

References

1. Cancer Today. , accessed: 04/23/2023.
2. Shore N.D., Ionescu-Ittu R., Laliberté F., et al. (2021). Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer, 19(6), 480–490.
3. Huy, V.X (2011). Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị ung thư tuyến tiền liệt giai đoạn IV
4. Tâm L.T.K. Đánh giá kết quả điều trị nội tiết ung thư tuyến tiền liệt giai đoạn IV. 136.
5. Ryan C.J., Smith M.R., Fizazi K., et al. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16(2), 152–160.
6. Ryan C.J., Smith M.R., Fizazi K., et al. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16(2), 152–160.
7. Gandaglia G., Abdollah F., Schiffmann J., et al. (2014). Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate, 74(2), 210–216.
8. Kyriakopoulos C.E., Chen Y.-H., Carducci M.A., et al. (2018). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol, 36(11), 1080–1087.